ニュース

本社移転のお知らせ

拝啓 時下ますますご清栄のこととお慶び申し上げます。 平素は格別のお引き立てを賜り、厚く御礼申し上げます。 さて当社は、本社事務所を平成28年12月22日(木)付で下記のとおり移転する運びとなりましたので、謹んでご案内いたします。 これを機に社員一同気持ちを新たに業務に精励する所存ですので何卒変わらぬご愛顧を賜りますようお願い申し上げます。 今後とも変わらぬお引き立てを賜りますよう、よろしくお願い申し上げます。                             記 ■新住所: 〒103-0015 東京都中央区日本橋箱崎町35番3 …

大阪大学、香川大学とリポソーム製剤の開発に関する共同研究契約締結のお知らせ

2016年7月27日 会社名    株式会社レグイミューン 代表者名    代表取締役社長   小須田 建 三 問い合わせ  経営管理部     野 澤 三知代   (TEL 03-5614-0007) 2016年7月25日、当社は、国立大学法人大阪大学(以下、「大阪大学」)並びに国立大学法人香川大学(以下、「香川大学」)と、松崎高志特任助教(大阪大学大学院医学研究科)らが独自に開発したGMP対応のインラインリポソーム製剤装置(以下、SOLIDシステム)を使用したリポソーム製剤に関する共同研究契約を締結いたしました。SOLIDシステム …

代表取締役会長新設並びに代表取締役社長交代の件

                       代表取締役社長交代のお知らせ 拝啓 時下ますますご清栄のこととお慶び申し上げます 平素は格別のお引き立てを賜り、厚く御礼申し上げます さて 私儀  平成28年7月1日付をもって代表取締役社長を交代いたしました 社長在任中は格別のお引き立てを賜り誠にありがとうございました。今後も、代表取締役会長として引き続き会社をサポートして参ります なお 後任社長には小須田 建三が就任いたしましたので 何とぞ私同様のお引き立てを賜りますようお願い申し上げます                         …

REGiMMUNE appoints new board members

REGiMMUNE Corporation (RGI) Appointed  Joseph “Joe” McCracken as a board Tokyo, Japan., Dec 25, 2015 – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Joseph McCracken to its Board of Directors. Dr. McCracken currently advises biopharmaceutica …

Ⅰ型糖尿病の予防と治療に関するJDRF及びファイザーとの共同研究開発締結のお知らせ

2015年4月15日 会社名   株式会社レグイミューン 代表者名   代表取締役社長   石井 保之 問い合わせ  取締役経営管理部長 小須田建三   (TEL 03-5614-0007) レグイミューンとJDRFとファイザーがTregを誘導するⅠ型糖尿病の予防と治療に関する共同研究開発で提携 ―モデル動物を用いて糖尿病の予防と治療効果を示す抗原特異的免疫治療法の確立を目指す― 2015年4月15日、当社は、JDRF(国際若年性糖尿病研究財団:米国 ニューヨーク州)とPfizer Inc社(米国 ニューヨーク州)と共同で、当社が所有 …

米国子会社本社移転のお知らせ

米国子会社の本社オフィスをサンフランシスコ市からバークレー市へ移転させました。新住所は以下の通りです。 2600 Tenth Street – Suite 604A Berkeley, CA 94710 移転先はアクセスページをご覧ください。

本社移転のご案内

拝啓 時下ますますご清栄のこととお慶び申し上げます。 平素は格別のお引き立てを賜り、厚く御礼申し上げます。 さて当社は、業務拡充に伴い本社事務所を平成26年6月16日(月)付で下記のとおり移転する運びとなりましたので、謹んでご案内いたします。 これを機に社員一同気持ちを新たに業務に精励する所存ですので何卒変わらぬご愛顧を賜りますようお願い申し上げます。 今後とも変わらぬお引き立てを賜りますよう、よろしくお願い申し上げます。                             記 ■新本社営業開始日 : 平成26年6月16日(月) …

第三者割当増資により9.2億円のシリーズD資金調達を実施

レグイミューン、第三者割当増資により9.2億円のシリーズD資金調達を実施 ~RGI-2001に次ぐ後続のパイプラインの開発を本格化~ 株式会社レグイミューン(本社:東京都中央区、代表取締役社長(CEO):森田 晴彦、以下 レグイミューン)は、下記8社および運営するファンドを引受先に合計9.2億円となるシリーズDの資金調達を2014年2月14日付で完了いたしました。 日本アジア投資株式会社(東京都千代田区、代表取締役社長:細窪 政) 日本ベンチャーキャピタル株式会社(東京都港区、代表取締役社長:奥原 主一) SMBCベンチャーキャピタル …

USオフィスを移転しました。

USラボ&オフィスをサンタクララ市からサンフランシスコ市へ移転させました。 移転先はアクセスページをご覧ください。

REGiMMUNE appoints new board members

Santa Clara, CA and TOKYO — April 12, 2013 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has appointed Mr. Nakamura, Dr. Misawa, Dr. Matsuishi and Mr.Hirai the as non-executive director. Mr. Nakamura is currently the head …

RGI-2001 was granted Orphan Drug Designation from FDA

RGI-2001 has been granted Orphan Drug Designation for RGI-2001 from FDA Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food � …

REGiMMUNE Appoints a new board member

REGiMMUNE Corporation announced today that it has appointed Mr. Kohtaro Toda as a board member. He is currently an investment manager of Japan Asia Investment Co., Ltd. (JAIC), a Japanese venture capital firm with $1 billion under management. The addition of this new ma …

reVax patent has been granted

Basis patent for the target specific tolerance induction by GalCer liposome, reVax technology, has been granted Tokyo, JAPAN–(Nov 28, 2011) – REGiMMUNE Corp. (“Company”) announces that the Japanese Patent Office has granted a patent, containing c …

Publication of GvHD paper

REGiMMUNE Corp. Announces Publication of preclinical GvHD data Tokyo, JAPAN–(Nov 22, 2010) – REGiMMUNE Corp. (“Company”) is pleased to announce the acceptance and publication of the paper entitled “Pharmacological Expansion of Donor-derived …

Astellas and REGiMMUNE to Collaborate on New Vaccine Technology

Tokyo, Japan and Mountain View, CA – July 22, 2009 – REGiMMUNE Corporation today announced that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology. The partnership will combi …

REGiMMUNE to Present at the 50th ASH Annual Meeting

Mountain View, CA – December 5, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company’s potential therapeutic treatment for Graft versus …

Relocation of Headquarters in Japan

Japan headquarters has been relocated to following address as of August 1st 2008. 1-7-8 Kaigan Tokyo Industrial Trade Center 607 (6th Floor) Minato-ku Tokyo 105-0022 JAPAN for detailed direction, please see accesss page

REGiMMUNE Raises $8,000,000 in Series B Financing

Mountain View, CA and TOKYO – May 6, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today that it has closed its Series B financing for a total of $8 million U.S. Proceeds from the financing will be used to advance the company’s lead …

REGiMMUNE Closes First Tranche of Series B Financing

Mountain View, CA and TOKYO – Feb 1, 2008 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised a total of $6 million U.S. in a Series B venture capital financing from new and existing investors. The original lead inves …

REGiMMUNE Licensed Immunoregulatory Compound from KIRIN Pharma

MOUNTAIN VIEW, CA and TOKYO – Jan 28, 2008 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that the company recently signed a license agreement with Kirin Pharma Company, Limited for the exclusive worldwide rights to use Kirin …

Robert NEGRIN, M.D. appointed to Scientific and Clinical Advisor

REGiMMUNE today announces it has appointed Dr. Professor Robert NEGRIN as a new Scientific and Clinical Adviser to the company. Dr. Negrin is Professor of Medicine in the Division of Blood and Marrow Transplantation at Stanford University. He also holds the positions of …

REGiMMUNE Receives Grant Award from METI

Mountain View, Calif. and Tokyo, Japan – August 7, 2007 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today it has been awarded a grant from the Japanese Ministry of Economy, Trade and Industry (METI). REGiMMUNE received the grant under …

REGiMMUNE established broad collaboration with RIKEN

REGiMMUNE Establishes Broad Collaboration with RIKEN MOUNTAIN VIEW, CA and TOKYO — Mar 22, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has enter into an Intellectual Property and Industry-Academia Collab …

REGiMMUNE Announces Series A Financing

MOUNTAIN VIEW, CA and TOKYO–Feb 21, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised $4.2 million U.S. in a Series A venture capital financing from new and existing investors. The original lead inv …

Relocation of US Office

Mountain View, CA and Tokyo, Japan — February 1, 2007 — REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today the relocation of its US offices from San Jose to Mountain View, California.

REGiMMUNE Announces Appointment to the Board

Tokyo, Japan – Nov. 29, 2006 – REGiMMUNE Corporation announced today the appointment of Mr. Hiroki NARITA, the Deputy General Manager, Investment Group, NIF SMBC Ventures, Japan, to its Board of Directors. Mr. Narita has participated in the investment of approximately $ …

REGiMMUNE Opens a New Subsidiary in US West Coast.

Tokyo, Japan – Nov. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the opening of a new subsidiary in the United States in San Jose, California. “REGiMMUNE is planning to enter clinical studies in the US in 2009, for autoimm …

REGiMMUNE Announces Appointments to Scientific Advisory Board

Tokyo, Japan, – Sept. 20, 2006 – REGiMMUNE Corporation announced today the appointment of Dr. Yasuyuki ISHII, Team Leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology (RCAI), “We are delighted to have a world-renowne …

Entered into a License Agreement with RIKEN

Tokyo, Japan –Sep. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced that it has entered into a license agreement with RIKEN. Under the agreement, an exclusive right to market/sublicense pharmaceutical products based on RIKEN’s …

Relocated Headquarters

Tokyo, Japan – Sept. 1, 2006 – REGiMMUNE Corporation has relocated its headquarters from Toranomon, Tokyo to: 3-12-5 Shibaura, Ishizaka Bldg. 6F Minato-ku, Tokyo 108-0023 Japan phone +81-3-3456-0820

Completed Seed Round Financing

Tokyo, Japan –Aug. 15, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced the closing of the Company’s Seed Round Financing, adding $1.6 million in additional new equity. New venture capital investors NIF SMBC Ventures, Nikko AntFa …